Navigation Links
Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Date:12/10/2008

SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the commencement of patient dosing for a Phase 1 clinical trial for a bisphosphonate administered with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) injection. This study will explore the safety, tolerability and pharmacokinetics of SC administration of a bisphosphonate plus rHuPH20. Currently, injectable bisphosphonates must be administered intravenously (IV).

"We are pleased that the first clinical trial is underway for our bisphosphonate program, our third proprietary product development initiative to enter clinical studies," stated Jonathan Lim, M.D., President and CEO of Halozyme Therapeutics. "The bisphosphonate program joins insulin, for diabetes, and Chemophase, for superficial bladder cancer, our other two proprietary programs in clinical development. The goal of Halozyme's bisphosphonate program is to provide an alternative dosage formulation that may offer greater convenience, compliance and tolerability to patients for the treatment of osteoporosis."

This Phase 1 dose ranging clinical trial will assess the safety, tolerability and pharmacokinetics of a bisphosphonate with and without co-administration of rHuPH20 across a range of bisphosphonate concentrations and volumes and various rHuPH20 doses. The study will also compare SC administration of a bisphosphonate plus rHuPH20 to IV bisphosphonate alone.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for t
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
2. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
5. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
6. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
7. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
8. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
9. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced the appointment of ... Pincus LLC, to the Amgen Board of Directors. ... and the deep, global experience he brings in the biopharmaceuticals ... , chairman and chief executive officer of Amgen. "Fred,s breadth of ... Mr. Hassan has been Partner and Managing Director ...
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015  Growth of the U.S. ... they bring former prescription users to the OTC market. ... forecasts robust Rx-to-OTC switch activity over the next ... along with many new brands entering the market into ... the next five years (even those with low to ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty biopharmaceutical ... Monday, August 1, 2011 before the opening of the U.S. ... that day at 10:00 a.m. ET to discuss results and ... be used during the call will be available on the ...
... 18, 2011 Reportlinker.com announces that ... available in its catalogue: ... BRICS (Brazil, Russia, India, China, South ... http://www.reportlinker.com/p0573105/Neurosurgical-Products-Market-Outlook-in-BRICS-Brazil-Russia-India-China-South-Africa-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging Neurosurgical ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011 2Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011 3Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 2Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 3Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 4Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 5Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 6Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 7Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 8Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 9Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 10Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 11Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 12Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 13Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 14Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 15
(Date:7/30/2015)... ... 31, 2015 , ... Reduce Human Error on the Drug ... and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice ... and device firms reduce manufacturing errors by 50 percent or more, will conduct ...
(Date:7/30/2015)... ... 2015 , ... On July 22nd the Bradenton Herald reported the ... for controlling the heroin outbreak. Ultimately the committee expressed lack of funding, and the ... heroin crisis in North Florida. The task force has proposed to instate counselors to ...
(Date:7/30/2015)... IL (PRWEB) , ... July 30, 2015 , ... ... of patented products, announces I am Fine, an app invention that can help ... billion by 2017," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:7/30/2015)... ... 30, 2015 , ... The Clinical Data Interchange Standards Consortium ... announce that data standards for clinical research in the areas of Schizophrenia, Hepatitis ... . These three Therapeutic Area (TA) standards were developed per the CDISC global, ...
(Date:7/30/2015)... ... ... In an effort to provide the twenty four hour continuous care desired by his ... The decision will also allow him to spend more time in the office with ... to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always provided excellent care ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2
... Government Medical College Hospital not in the list of collages ... ,There is an increased bitterness among the local people ... health of not including K. A. P. Viswanatham Government Medical ... ,All India Institute of Medical Sciences (AIIMS), New Delhi. ...
... Shire Council decides to pay for the services of another ... ,The council have decided to give the Condobolin Aboriginal Health ... as a general practitioner and be a second visiting medical ... VMO had resigned from his post in February and the ...
... and Zoloft from pharmaceuticals Merck and Pfizer respectively are to ... ,Zocor, which is a cholesterol-reducing drug from Merck and ... month. It was reported that Merck's patent for Zocor expires ... money had earlier reported that the total sales in 2005 ...
... successfully completed with 96 percent of children under five being ... Days (NIDs). // ,Carried out on ... to cover 22 million children under the age of five, ... ,The campaign was triggered by the affirmation ...
... New Zealand are welcoming a Pharmac decision to fund long-acting ... ,The government agency that purchases drugs announced yesterday that ... is also known by its trade name, Lantus. ... priced at $5 million, reduces the risk of hypo ...
... test every resident in the city aged between 14 and ... campaign considered to be the most comprehensive in the history ... routine. ,Several thousands of free oral testing kits ... a person's HIV status within 20 minutes. The program uses ...
Cached Medicine News:Health News:Increased Demand For Up-gradation Local Hospital In Tiruchy 2Health News:Patency On Two Drugs From Merck & Pfizer’s To Expire Soo 2
... BioTwist RC implant is molded from Poly-L-Lactide ... bioresorbable fixation, which include radiolucency and a ... ,The simple screw-in method of insertion ... when repairing the rotator cuff. The ...
... just got better. How can one of ... Simply by becoming more convenient to use ... arthroscopic. The TwinFix Suture Anchor with Needles ... unique, convenient and timesaving anchor inserter and ...
The unique design of the TWINFIX Suture Anchors combines high resistance to pullout from our patented thread design with optimal knot tying from the DURABRAID suture....
... Micro Anchor is the smallest, strongest ... flexibility in placement into even the ... with 3-0 or 4-0 ETHIBOND EXCEL ... or cutting swaged needles. The kit ...
Medicine Products: